Validation of Copy Number Changes by MLPA as Predictors of Relapse in Wilms Tumor
N/A
N/A
Both
Kidney Cancer
Trial Information
Validation of Copy Number Changes by MLPA as Predictors of Relapse in Wilms Tumor
OBJECTIVES:
- To analyze 250 favorable-histology Wilms tumor (FHWT) samples from patients registered
on NWTS4 for gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q by subtelomeric
multiplex ligation-dependent probe amplification (MLPA), and to determine their
association with relapse-free and overall survival.
- To develop a robust multiplex MLPA test using multiple synthesized probes to those
targets identified as significantly associated with relapse in Aim 1.
- To validate the multiplex MLPA test designed and tested in Aim 2 on an independent set
of 1727 FHWT and 250 anaplastic WT registered on NWTS-5.
OUTLINE: Archived DNA samples are analyzed for gain of 1q and 15q, and loss of 1p, 16q, 17p,
and 22q by MLPA. Assay results are then researched for accuracy, clinical validity,
sensitivity, precision, and potential analytical interferences.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- DNA samples from FHWT patients registered on:
- NWTS-4
- NWTS-5 with focal and diffuse anaplasia tumors
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Validation of copy number changes (gain of 1q and 15q, and loss of 1p, 16q, 17p, and 22q) in FHWT by the MLPA assay
Safety Issue:
No
Principal Investigator
Elizabeth J. Perlman, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Ann & Robert H Lurie Children's Hospital of Chicago
Authority:
United States: Federal Government
Study ID:
CDR0000730403
NCT ID:
NCT01576198
Start Date:
April 2012
Completion Date:
Related Keywords:
- Kidney Cancer
- Wilms tumor and other childhood kidney tumors
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Wilms Tumor
Name | Location |
|---|
